FY2029 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for Invivyd in a research note issued on Tuesday, February 4th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.41 for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.57) per share.

A number of other brokerages also recently commented on IVVD. Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research report on Monday. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $7.89.

Invivyd Stock Up 17.9 %

Shares of IVVD opened at $1.25 on Wednesday. The stock has a fifty day simple moving average of $0.52 and a two-hundred day simple moving average of $0.82. Invivyd has a 52-week low of $0.35 and a 52-week high of $5.10.

Insider Buying and Selling at Invivyd

In related news, Director Terrance Mcguire sold 150,000 shares of Invivyd stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the transaction, the director now owns 4,538,079 shares in the company, valued at approximately $2,768,228.19. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 816,466 shares of company stock valued at $423,214 over the last quarter. 17.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently added to or reduced their stakes in IVVD. State Street Corp increased its position in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the period. Marshall Wace LLP grew its stake in Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Invivyd during the 2nd quarter worth about $421,000. Cubist Systematic Strategies LLC raised its position in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares during the period. 70.36% of the stock is currently owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.